These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 21191411

  • 1. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
    Bensussan A, Remtoula N, Sivori S, Bagot M, Moretta A, Marie-Cardine A.
    J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
    [Abstract] [Full Text] [Related]

  • 2. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.
    Ortonne N, Le Gouvello S, Tabak R, Marie-Cardine A, Setiao J, Berrehar F, Nghe-Tang A, Martin N, Bagot M, Bensussan A.
    Exp Dermatol; 2012 Jun; 21(6):461-3. PubMed ID: 22621189
    [Abstract] [Full Text] [Related]

  • 3. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
    Dulphy N, Berrou J, Campillo JA, Bagot M, Bensussan A, Toubert A.
    J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
    [Abstract] [Full Text] [Related]

  • 4. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.
    Ortonne N, Le Gouvello S, Mansour H, Poillet C, Martin N, Delfau-Larue MH, Leroy K, Farcet JP, Bagot M, Bensussan A.
    J Invest Dermatol; 2008 Feb; 128(2):465-72. PubMed ID: 17703174
    [Abstract] [Full Text] [Related]

  • 5. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M, Musette P, Bagot M, Boumsell L, Bensussan A.
    Blood; 2002 Aug 01; 100(3):1019-25. PubMed ID: 12130517
    [Abstract] [Full Text] [Related]

  • 6. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E, Schiavon V, D'Incan M, Echchakir H, Musette P, Ortonne N, Boumsell L, Moretta A, Bensussan A, Bagot M.
    J Invest Dermatol; 2004 Mar 01; 122(3):820-3. PubMed ID: 15086570
    [Abstract] [Full Text] [Related]

  • 7. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N, Schiavon V, Bounfour T, Dessirier V, Ortonne N, Olive D, Ram-Wolff C, Michel L, Sicard H, Marie-Cardine A, Bagot M, Bensussan A, Schmitt C.
    Cytometry A; 2014 Oct 01; 85(10):869-82. PubMed ID: 25044837
    [Abstract] [Full Text] [Related]

  • 8. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
    Michel L, Jean-Louis F, Begue E, Bensussan A, Bagot M.
    Blood; 2013 Feb 21; 121(8):1477-8. PubMed ID: 23429988
    [No Abstract] [Full Text] [Related]

  • 9. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS, Newton SM, Wysocka M, Troxel AB, Hess SD, Richardson SK, Lin JH, Benoit BM, Kasprzycka M, Wasik MA, Rook AH.
    J Invest Dermatol; 2008 Feb 21; 128(2):473-80. PubMed ID: 17713571
    [Abstract] [Full Text] [Related]

  • 10. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH, Shane RB, Geng Y, Showe LC, Everetts SE, Presky DH, Wysocka M, Moore JS, Rook AH.
    J Invest Dermatol; 2001 Jul 21; 117(1):119-27. PubMed ID: 11442758
    [Abstract] [Full Text] [Related]

  • 11. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
    Bahler DW, Hartung L, Hill S, Bowen GM, Vonderheid EC.
    Cytometry B Clin Cytom; 2008 May 21; 74(3):156-62. PubMed ID: 18061949
    [Abstract] [Full Text] [Related]

  • 12. Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor.
    Magazin M, Poszepczynska-Guigné E, Bagot M, Boumsell L, Pruvost C, Chalon P, Culouscou JM, Ferrara P, Bensussan A.
    J Invest Dermatol; 2004 Jan 21; 122(1):111-8. PubMed ID: 14962098
    [Abstract] [Full Text] [Related]

  • 13. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
    Moins-Teisserenc H, Daubord M, Clave E, Douay C, Félix J, Marie-Cardine A, Ram-Wolff C, Maki G, Beldjord K, Homyrda L, Michel L, Bensussan A, Toubert A, Bagot M.
    J Invest Dermatol; 2015 Jan 21; 135(1):247-257. PubMed ID: 25158034
    [Abstract] [Full Text] [Related]

  • 14. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, Klemke CD.
    J Invest Dermatol; 2009 Dec 21; 129(12):2875-85. PubMed ID: 19626037
    [Abstract] [Full Text] [Related]

  • 15. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells.
    Nikolova M, Tawab A, Marie-Cardine A, Bagot M, Boumsell L, Bensussan A.
    J Invest Dermatol; 2001 May 21; 116(5):731-8. PubMed ID: 11348462
    [Abstract] [Full Text] [Related]

  • 16. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
    Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, Abuzahra F, Bowman E, Roszkiewicz J, Bieber T, Tüting T.
    Br J Dermatol; 2005 Feb 21; 152(2):258-64. PubMed ID: 15727636
    [Abstract] [Full Text] [Related]

  • 17. mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome.
    Bénard A, Cavaillès P, Boué J, Chapey E, Bayry J, Blanpied C, Meyer N, Lamant L, Kaveri SV, Brousset P, Dietrich G.
    J Invest Dermatol; 2010 May 21; 130(5):1337-44. PubMed ID: 20107485
    [Abstract] [Full Text] [Related]

  • 18. Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcepsilonRIgamma and CD3zeta.
    Westgaard IH, Berg SF, Vaage JT, Wang LL, Yokoyama WM, Dissen E, Fossum S.
    J Leukoc Biol; 2004 Dec 21; 76(6):1200-6. PubMed ID: 15356098
    [Abstract] [Full Text] [Related]

  • 19. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N, Huet D, Gaudez C, Marie-Cardine A, Schiavon V, Bagot M, Musette P, Bensussan A.
    Blood; 2006 May 15; 107(10):4030-8. PubMed ID: 16418328
    [Abstract] [Full Text] [Related]

  • 20. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.
    Bouaziz JD, Ortonne N, Giustiniani J, Schiavon V, Huet D, Bagot M, Bensussan A.
    J Invest Dermatol; 2005 Dec 15; 125(6):1273-8. PubMed ID: 16354199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.